Global CRO ClinTec GmbH Ranked in HSBC International Track 100

May 09, 2011 -- Global Clinical Research Organisation (CRO) ClinTec International has been ranked number 69 in the HSBC International Track 100 which was released in the broadsheet supplement of the Sunday Times yesterday. The International Track 100 ranks Britain’s private companies with the fastest growing international sales and has acknowledged ClinTec’s rapid sales growth and global expansion over the past year.

ClinTec has grown organically since its inception by Founder, President and CEO Dr Rabinder Buttar in 1997 and now operates in over 40 countries worldwide, providing specialist clinical support services to clients including 11 of the top 25 pharmaceutical companies, plus innovative biotech and medical device organisations.

Commenting on the achievement, Dr Buttar, stated “I am extremely pleased that the International Track 100 has listed ClinTec within their 2011 league table. This type of recognition continuously motivates our teams across the world and in turn we can continuously deliver excellence in clinical research to our pharmaceutical clients in a fast, flexible and focused manner”.

This achievement comes soon after ClinTec was awarded the prestigious Queens Award for Enterprise in the Category of International Trade in March 2011.

About ClinTec International

ClinTec International is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.

In addition to ClinTec International’s vast expertise in oncology, the organisation has also conducted over 400 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused? approach to clinical research ensures an added advantage to the drug development process. The organisations range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

For further information please contact:

Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or bbal@clintec.com

For more information about ClinTec, please visit www.clintec.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on: 00 44 207 861 3019. E-mail: t.jervis@defacto.com.